Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 7))	289,599	808,576	967,489	1,120,693
Depreciation	259	436	695	872
Research and development (including stock-based compensation (Note 7))	114,192	338,755	283,913	445,501
Total operating expenses	404,050	1,147,767	1,252,097	1,567,066
Loss from operations	(404,050)	(1,147,767)	(1,252,097)	(1,567,066)
Other expense (income):
Gain on extinguishment of liabilities		(718,580)		(718,580)
Interest expense	97,304	93,662	189,800	192,101
Total other expense (income)	97,304	(624,918)	189,800	(526,479)
Net loss	(501,354)	(522,849)	(1,441,897)	(1,040,587)
Net loss attributable to the noncontrolling interest	523	507	3,692	1,014
Net loss applicable to Bion's common stockholders	$ (500,831)	$ (522,342)	$ (1,438,205)	$ (1,039,573)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.06)	$ (0.04)
Weighted-average number of common shares outstanding: Basic and diluted (in shares)	26,382,778	24,233,123	26,021,254	24,150,108